# Thymosin Alpha-1 Injection: How It Is Given in Studies

> Thymosin Alpha-1 injection, explained from the research: the subcutaneous route used in every major trial, the dosing schedules studied by setting, the roughly 2-hour half-life, and why it is supplied freeze-dried. No human dosing advice.

The route, the schedules, and the handling notes from the literature - reported as research data, with no instruction to administer anything.

## The short version

Here is the plain version of how the Thymosin Alpha-1 injection works in the research, before the specifics. Nothing here is a how-to - it describes what was done in studies. In essentially every trial, the peptide is given as a subcutaneous injection, meaning a small shot into the fat just under the skin, the same way many people are given insulin. It is not taken as a pill, because the stomach would destroy it. It comes as a freeze-dried powder that has to be mixed with sterile liquid before use, which is one of the things people new to peptides find fiddly. The dose is small (milligram scale) and the schedule depends on the setting - twice a week for hepatitis, more often for a short stretch in sepsis trials. The drug clears the blood in a few hours. Because it is not an approved US product, there is no validated dose for self-use, and we do not provide one.

## The route: subcutaneous, in essentially every trial

The Thymosin Alpha-1 injection is subcutaneous - delivered into the tissue just beneath the skin - and that route is consistent across the clinical literature [6]. It is a peptide, so it is not given orally; aminopeptidases in the gut and blood degrade it, and it is supplied lyophilized (freeze-dried) precisely because it needs reconstitution and careful handling [12]. Mechanistic studies used in vitro and ex vivo systems and preclinical work used in vivo murine models, but the human and clinical route of record is the subcutaneous shot [6]. The pharmacology monograph documenting the marketed regimen describes the same subcutaneous delivery [4].

## Schedules studied by setting

Injection schedules in the studies follow the setting. For chronic hepatitis B and C, the marketed thymalfasin schedule is 1.6 mg subcutaneous twice weekly [4]. In the sepsis RCTs, the protocol intensified to 1.6 mg subcutaneous every 12 hours for five to seven days (ETASS and TESTS) [2][3]. COVID-19 cohorts used 1.6 mg subcutaneous daily [6], and cancer combination work used 1.6 mg twice weekly, with one lung-cancer adjunct study running weekly injections for up to 12 months [7]. The single-dose research range spans 0.8-6.4 mg, with multiple-dose regimens of 1.6-16 mg over five to seven days [6]. These are reported as study parameters tied to specific populations, not as instructions.

## What happens after the shot

Pharmacokinetically the injected peptide is short-lived. Human data describe an elimination half-life of roughly 2 hours, peak levels at about 1-2 hours, and blood concentrations returning toward baseline within about 24 hours; an in vitro study measured approximately 127 +/- 11 minutes [12]. It distributes into extracellular fluid, does not extensively bind plasma proteins, and is cleared by aminopeptidase degradation [12]. That short window is one reason chronic regimens repeat the injection rather than relying on a depot - and why researchers have experimented with sustained-release microsphere formulations to stretch the exposure [13].

## Handling, formulation, and the quality caveat

Two practical realities shape the injection in the real world. First, formulation: the peptide is supplied freeze-dried and must be reconstituted with sterile diluent and handled aseptically, a usability hurdle people new to lyophilized peptides report struggling with [12]. Second, and more important: outside an approved-drug setting, there is no guarantee the vial is what the label says. Thymosin Alpha-1 is not FDA-approved for US marketing, so a research-grade injectable carries no assurance of purity, content, sterility, or identity [6]. The clean tolerability record - injection-site reactions as the dominant event across 600,000+ patients - was built with regulated drug, not with an unverified research vial [9]. That distinction is the whole point of reading this as a case file rather than a sales page.

---

The unredacted file on Thymosin Alpha-1: every study logged and cited, the null result and the not-approved status stamped in plain sight, the banned brand name blacked out on purpose - a research digest, not a clinic, a vendor, or a prescription.